International Assets Investment Management LLC Acquires New Shares in Catalent, Inc. (NYSE:CTLT)

International Assets Investment Management LLC acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the fourth quarter, HoldingsChannel reports. The fund acquired 14,962 shares of the company’s stock, valued at approximately $6,720,000.

Other institutional investors have also recently bought and sold shares of the company. Cetera Advisor Networks LLC lifted its position in shares of Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after buying an additional 130 shares during the last quarter. Mackay Shields LLC increased its stake in shares of Catalent by 0.6% in the first quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock worth $2,856,000 after purchasing an additional 149 shares during the period. Wetherby Asset Management Inc. increased its stake in shares of Catalent by 5.1% in the first quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock worth $557,000 after purchasing an additional 243 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in shares of Catalent by 1.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock worth $953,000 after purchasing an additional 252 shares during the period. Finally, Covestor Ltd increased its stake in shares of Catalent by 84.9% in the first quarter. Covestor Ltd now owns 562 shares of the company’s stock worth $62,000 after purchasing an additional 258 shares during the period.

Catalent Stock Down 1.1 %

Shares of CTLT opened at $56.30 on Monday. The business’s 50 day simple moving average is $56.99 and its 200-day simple moving average is $47.91. Catalent, Inc. has a one year low of $31.45 and a one year high of $64.46. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a market capitalization of $10.18 billion, a P/E ratio of -8.28, a PEG ratio of 6.07 and a beta of 1.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $0.62 EPS. The firm’s quarterly revenue was down 10.2% compared to the same quarter last year. As a group, sell-side analysts predict that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CTLT. StockNews.com initiated coverage on Catalent in a research note on Thursday. They issued a “sell” rating on the stock. Stephens restated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Barclays boosted their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. UBS Group restated a “neutral” rating and set a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.